• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Onconetix Inc. (Amendment)

    6/10/24 11:04:36 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONCO alert in real time by email
    SC 13G/A 1 ea0207523-13ga1hernan_oncon.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Amendment No. 1)*

     

    Under the Securities Exchange Act of 1934

     

    Onconetix, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.00001 per share

    (Titles of Class of Securities)

     

    09610B 108

    (CUSIP Number)

     

    June 6, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☐Rule 13d-1(c)

     

    ☒Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out of a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1

    NAME OF REPORTING PERSON

     

    Joseph Hernandez

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF
    SHARES

    BENEFICIALLY

    OWNED BY

    EACH
    REPORTING PERSON
    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

    12

    TYPE OF REPORTING PERSON

     

    IN

     

    2

     

     

    Item 1(a).  Name of Issuer:

     

    Onconetix, Inc.

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    201 E. Fifth Street, Suite 1900

    Cincinnati, Ohio 45202

     

    Item 2(a). Name of Person Filing

     

    Joseph Hernandez (the “Reporting Person”)

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The principal business address of the Reporting Person is:

    15 East Putnam Avenue

    Greenwich, CT 06830

     

    Item 2(c). Citizenship

     

    United States of America

     

    Item 2(d). Title of Class of Securities

     

    Common Stock, par value $0.00001 per share

     

    Item 2(e). CUSIP Number

     

    09610B108

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
           
      (f) ☐ Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
           
      (g) ☐ Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
           
      (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
           
      (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
           
      (j) ☐ Non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
           
      (k) ☐ Group in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240. 13d-1(b)(1)(ii)(J), please specify the type of institution: ______________ .

     

    3

     

     

    Item 4. Ownership

     

      (a) Amount beneficially owned:

     

    See Item 9 on the cover page hereto.

     

      (b) Percent of class:

     

    See Item 11 on the cover page hereto.

     

      (c) Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

     

    See response to Item 5 on the cover page hereto.

     

    (ii)Shared power to vote or to direct the vote:

     

    See response to Item 6 on the cover page hereto.

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    See response to Item 7 on the cover page hereto.

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    See response to Item 8 on the cover page hereto.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    4

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: June 7, 2024  
       
      /s/ Joseph Hernandez
      Name: Joseph Hernandez

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations

    (See 18 U.S.C. 1001)

     

    5

     

    Get the next $ONCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONCO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

      Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) (the "Company") announced that it received a Staff delisting letter from The Nasdaq Capital Market ("Nasdaq") on May 20, 2025 indicating that the Company's failure to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 (the "10-Q") is in violation of Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule"). This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange C

      5/22/25 4:50:00 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

      Cincinnati, OH, April 30, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) (the "Company") announced that it received a Staff delisting letter from The Nasdaq Capital Market ("Nasdaq") on April 24, 2025 indicating that the Company's failure to file its Annual Report on Form 10-K for the fiscal year ended December 30, 2024 is in violation of Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule").   This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.  As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission

      4/30/25 6:13:39 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.

      CINCINNATI, April 08, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") (formerly Blue Water Biotech Inc.) and Ocuvex Therapeutics, Inc. ("Ocuvex"), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options, today announced that they have signed a Non-Binding Letter of Intent contemplating a potential business combination transaction with Ocuvex. Andrew J. Oakley, Chairman of the Board of Onconetix, stated, "We are excited about the opportunity to combine forces with Ocuvex, whose pipeline of commercial and late c

      4/8/25 8:30:00 AM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Oakley Andrew John was granted 1,709 shares (SEC Form 4)

      4 - Onconetix, Inc. (0001782107) (Issuer)

      3/25/25 3:44:38 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Oakley Andrew John

      3 - Onconetix, Inc. (0001782107) (Issuer)

      3/7/25 6:07:11 AM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Interim CEO, CSO Schiess Ralph was granted 177,462 shares, increasing direct ownership by 36% to 673,365 units (SEC Form 4)

      4 - Onconetix, Inc. (0001782107) (Issuer)

      1/22/25 4:15:13 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCO
    SEC Filings

    See more
    • Onconetix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Onconetix, Inc. (0001782107) (Filer)

      5/22/25 5:10:57 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconetix Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Onconetix, Inc. (0001782107) (Filer)

      4/30/25 5:23:53 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Onconetix Inc.

      DEF 14A - Onconetix, Inc. (0001782107) (Filer)

      4/29/25 6:50:09 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Onconetix Inc.

      SC 13G - Onconetix, Inc. (0001782107) (Subject)

      11/14/24 11:19:35 AM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Onconetix Inc.

      SC 13D - Onconetix, Inc. (0001782107) (Subject)

      10/1/24 4:35:03 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Onconetix Inc.

      SC 13D - Onconetix, Inc. (0001782107) (Subject)

      10/1/24 4:35:03 PM ET
      $ONCO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCO
    Leadership Updates

    Live Leadership Updates

    See more
    • Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

      Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

      10/8/24 5:00:00 AM ET
      $ENTO
      $OCS
      $ONCO
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care